Literature DB >> 15449041

Phenotype and function of human natural killer cells purified by using a clinical-scale immunomagnetic method.

Wing Leung1, Rekha Iyengar, Thasia Leimig, Marti S Holladay, James Houston, Rupert Handgretinger.   

Abstract

Infection, disease relapse, graft failure, and graft-versus-host disease (GVHD) are significant adverse events associated with allogeneic bone marrow transplantation. Donor natural killer (NK) cells may be an ideal cell type for prevention or treatment of all these adverse events. Therefore, we investigated the phenotype and function of human NK cells purified by using a clinical-scale immunomagnetic method. We found that the NK cell purification procedures did not adversely affect the expression of killer cell immunoglobulin-like receptors, adhesion molecules, intracellular cytokines, perforin, and granzyme B. Purified NK cells had extensive proliferative capacity and potent antitumor activity when assessed using an immunodeficient mouse model. While all mice transplanted with unpurified mononuclear cells developed GVHD, none of the mice transplanted with purified NK cells did. NK cells were highly susceptible to lysis by antithymocyte globulin (ATG), whereas G-CSF had a minimal effect on their natural cytotoxicity. These results support future clinical investigation of the use of purified NK cells for adoptive immunotherapy in the absence of ATG.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15449041     DOI: 10.1007/s00262-004-0609-6

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  12 in total

1.  Blood dendritic cells suppress NK cell function and increase the risk of leukemia relapse after hematopoietic cell transplantation.

Authors:  Antonio Perez-Martinez; Rekha Iyengar; Kwan Gan; Thirachit Chotsampancharoen; Barbara Rooney; Marti Holladay; Manuel Ramírez; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-25       Impact factor: 5.742

2.  A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study.

Authors:  Stella M Davies; Robert Iannone; Todd A Alonzo; Yi-Cheng Wang; Robert Gerbing; Sandeep Soni; E Anders Kolb; Soheil Meshinchi; Paul J Orchard; Linda J Burns; Shalini Shenoy; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2019-12-21       Impact factor: 5.742

Review 3.  Perspective on the role of haploidentical transplantation in the management of hematologic malignancies: why do it?

Authors:  Gregory A Hale
Journal:  Curr Hematol Malig Rep       Date:  2007-07       Impact factor: 3.952

4.  Ex vivo generation of highly purified and activated natural killer cells from human peripheral blood.

Authors:  Satoru Saito; Yui Harada; Yosuke Morodomi; Mitsuho Onimaru; Kumi Yoshida; Ryoichi Kyuragi; Hisahiro Matsubara; Yoshikazu Yonemitsu
Journal:  Hum Gene Ther Methods       Date:  2013-08       Impact factor: 2.396

5.  NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba; Raul C Ribeiro; Stanley Pounds; Barbara Rooney; Teresa Bell; Ching-Hon Pui; Wing Leung
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

6.  Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies.

Authors:  B M Triplett; E M Horwitz; R Iyengar; V Turner; M S Holladay; K Gan; F G Behm; W Leung
Journal:  Leukemia       Date:  2009-02-12       Impact factor: 11.528

Review 7.  Immunotherapy in acute leukemia.

Authors:  Wing Leung
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

Review 8.  Expansion and activation of natural killer cells for cancer immunotherapy.

Authors:  Duck Cho; Dario Campana
Journal:  Korean J Lab Med       Date:  2009-04

Review 9.  Manufacturing Natural Killer Cells as Medicinal Products.

Authors:  Christian Chabannon; Bechara Mfarrej; Sophie Guia; Sophie Ugolini; Raynier Devillier; Didier Blaise; Eric Vivier; Boris Calmels
Journal:  Front Immunol       Date:  2016-11-15       Impact factor: 7.561

10.  Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma.

Authors:  W Leung; R Handgretinger; R Iyengar; V Turner; M S Holladay; G A Hale
Journal:  Br J Cancer       Date:  2007-07-31       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.